What is LightIntegra Technology?
Founded in 2009, LightIntegra Technology specializes in the development of advanced diagnostic tools designed to mitigate platelet refractoriness, a persistent challenge in clinical hematology. The company's flagship technology, ThromboLUX, serves as a sophisticated analytical instrument for the routine testing of platelet concentrates. By providing actionable insights into the quality and suitability of platelet units, the platform enables healthcare providers to optimize the allocation of resources between prophylactic and therapeutic applications. This precision-oriented approach positions LightIntegra as a vital contributor to the evolving landscape of personalized medicine and blood banking efficiency.
How much funding has LightIntegra Technology raised?
LightIntegra Technology has raised a total of $4.5M across 2 funding rounds:
Private Equity
$3.5M
Other Financing Round
$1M
Private Equity (2017): $3.5M, investors not publicly disclosed
Other Financing Round (2020): $1M led by Genome British Columbia and Genome Canada
Key Investors in LightIntegra Technology
Genome British Columbia and Genome Canada
Genome Canada is a national organization dedicated to driving economic growth and health innovation through strategic investments in genomics research and large-scale collaborative projects.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for LightIntegra Technology?
With the recent influx of capital, LightIntegra Technology is well-positioned to scale its commercial operations and expand the clinical adoption of the ThromboLUX system. The company's strategic roadmap likely involves deepening its integration within the Canadian healthcare ecosystem while exploring broader international markets. By leveraging its expertise in platelet diagnostics, the firm aims to enhance patient outcomes and reduce the economic burden associated with ineffective transfusion therapies. Future growth will likely be driven by continued research and development, alongside strategic partnerships that align with the company's mission to standardize platelet quality assessment on a global scale.
See full LightIntegra Technology company page
